Overview
Cranial electrotherapy stimulation (CES) delivers low electrical current through head or ear electrodes. It is distinct from tDCS, TMS and neurofeedback. In the United States, CES intended for insomnia or anxiety is Class II with special controls; CES intended to treat depression remains Class III.
Regulatory status is not proof that every claim or protocol works. Verify the exact model and labeled indication. Reviews have found heterogeneous, often small trials, so CES should not replace CBT-I, psychotherapy, medication management or urgent psychiatric care.
Benefits
Noninvasive and generally portable
May help selected anxiety or insomnia symptoms with an appropriately marketed device
No anesthesia or routine downtime
Can be evaluated as a time-limited adjunct with validated outcomes
The Procedure
1
Confirm indication and device
2
Safety screen
3
Use labeled protocol
4
Track and stop
Preparation
Review the device instructions, medication and implant history. Clean electrode sites and remove jewelry as directed. Do not alter prescribed psychiatric or sleep treatment without the treating clinician.
Recovery & Aftercare
Usually no downtime. Dizziness or drowsiness can occur; avoid driving after the first use until individual response is known.
Risks & Considerations
Possible skin irritation, tingling, headache, dizziness or drowsiness. Device labeling and contraindications vary. Implanted electronic devices and neurologic conditions require specific clinical review. Do not use CES to self-treat severe depression, mania, psychosis or suicidality; seek urgent care for acute psychiatric or neurologic danger.
Frequently Asked Questions
References
[1]
21 CFR 882.5800—Cranial Electrotherapy Stimulator
https://www.ecfr.gov/current/title-21/section-882.5800[2]
FDA Final Order: CES for Insomnia and Anxiety
https://www.federalregister.gov/documents/2019/02/08/2019-01664/neurological-devices-reclassification-of-the-cranial-electrotherapy-stimulator-intended-to-treat[3]
VA Evidence Review: Cranial Electrical Stimulation
https://www.ncbi.nlm.nih.gov/books/NBK537162/[4]
FDA Product Classification: CES for Depression (Class III)
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm?id=JXK
Your Privacy Choices